BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 24256244)

  • 21. Generation and characterization of induced pluripotent stem cells from a Parkinson's disease patient carrying the digenic LRRK2 p.G2019S and GBA1 p.N409S mutations.
    Oleksy C; Massart F; Goldwurm S; Arado A; Arena G; Boussaad I; Krüger R
    Stem Cell Res; 2023 Oct; 72():103212. PubMed ID: 37832355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impairment of proteasome and anti-oxidative pathways in the induced pluripotent stem cell model for sporadic Parkinson's disease.
    Chang KH; Lee-Chen GJ; Wu YR; Chen YJ; Lin JL; Li M; Chen IC; Lo YS; Wu HC; Chen CM
    Parkinsonism Relat Disord; 2016 Mar; 24():81-8. PubMed ID: 26797011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissecting the non-neuronal cell contribution to Parkinson's disease pathogenesis using induced pluripotent stem cells.
    Pons-Espinal M; Blasco-Agell L; Consiglio A
    Cell Mol Life Sci; 2021 Mar; 78(5):2081-2094. PubMed ID: 33210214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation.
    Bono F; Mutti V; Devoto P; Bolognin S; Schwamborn JC; Missale C; Fiorentini C
    Neurobiol Aging; 2021 Mar; 99():65-78. PubMed ID: 33422895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson's iPSC-derived dopamine neurons.
    Zambon F; Cherubini M; Fernandes HJR; Lang C; Ryan BJ; Volpato V; Bengoa-Vergniory N; Vingill S; Attar M; Booth HDE; Haenseler W; Vowles J; Bowden R; Webber C; Cowley SA; Wade-Martins R
    Hum Mol Genet; 2019 Jun; 28(12):2001-2013. PubMed ID: 30753527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons.
    Fernandes HJ; Hartfield EM; Christian HC; Emmanoulidou E; Zheng Y; Booth H; Bogetofte H; Lang C; Ryan BJ; Sardi SP; Badger J; Vowles J; Evetts S; Tofaris GK; Vekrellis K; Talbot K; Hu MT; James W; Cowley SA; Wade-Martins R
    Stem Cell Reports; 2016 Mar; 6(3):342-56. PubMed ID: 26905200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of patient-derived pluripotent stem cell-lines and CRISPR modified isogenic controls with mutations in the Parkinson's associated GBA gene.
    X-Q Chen C; Deneault E; Abdian N; You Z; Sirois J; Nicouleau M; Shlaifer I; Villegas L; Boivin MN; Gaborieau L; Karamchandani J; Beitel LK; Fon EA; Durcan TM
    Stem Cell Res; 2022 Oct; 64():102919. PubMed ID: 36130446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induced pluripotent stem cells: a tool for modeling Parkinson's disease.
    Bose A; Petsko GA; Studer L
    Trends Neurosci; 2022 Aug; 45(8):608-620. PubMed ID: 35667922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical Characteristics of iPSC-Derived Dopaminergic Neurons from N370S
    Grigor'eva EV; Kopytova AE; Yarkova ES; Pavlova SV; Sorogina DA; Malakhova AA; Malankhanova TB; Baydakova GV; Zakharova EY; Medvedev SP; Pchelina SN; Zakian SM
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901867
    [No Abstract]   [Full Text] [Related]  

  • 30. Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism.
    Okarmus J; Havelund JF; Ryding M; Schmidt SI; Bogetofte H; Heon-Roberts R; Wade-Martins R; Cowley SA; Ryan BJ; Færgeman NJ; Hyttel P; Meyer M
    Stem Cell Reports; 2021 Jun; 16(6):1510-1526. PubMed ID: 34048689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson's Disease.
    di Domenico A; Carola G; Calatayud C; Pons-Espinal M; Muñoz JP; Richaud-Patin Y; Fernandez-Carasa I; Gut M; Faella A; Parameswaran J; Soriano J; Ferrer I; Tolosa E; Zorzano A; Cuervo AM; Raya A; Consiglio A
    Stem Cell Reports; 2019 Feb; 12(2):213-229. PubMed ID: 30639209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons.
    Schwab AJ; Sison SL; Meade MR; Broniowska KA; Corbett JA; Ebert AD
    Stem Cell Reports; 2017 Dec; 9(6):1839-1852. PubMed ID: 29129681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic alterations in Parkinson's disease astrocytes.
    Sonninen TM; Hämäläinen RH; Koskuvi M; Oksanen M; Shakirzyanova A; Wojciechowski S; Puttonen K; Naumenko N; Goldsteins G; Laham-Karam N; Lehtonen M; Tavi P; Koistinaho J; Lehtonen Š
    Sci Rep; 2020 Sep; 10(1):14474. PubMed ID: 32879386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson's disease models.
    Burbulla LF; Zheng J; Song P; Jiang W; Johnson ME; Brundin P; Krainc D
    JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parkin Maintains Robust Pacemaking in Human Induced Pluripotent Stem Cell-Derived A9 Dopaminergic Neurons.
    Pu J; Lin L; Jiang H; Hu Z; Li H; Yan Z; Zhang B; Feng J
    Mov Disord; 2023 Jul; 38(7):1273-1281. PubMed ID: 37166002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcriptomics analysis of human iPSC-derived dopaminergic neurons reveals a novel model for sporadic Parkinson's disease.
    Krauskopf J; Eggermont K; Madeiro Da Costa RF; Bohler S; Hauser D; Caiment F; de Kok TM; Verfaillie C; Kleinjans JC
    Mol Psychiatry; 2022 Oct; 27(10):4355-4367. PubMed ID: 35725899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Demonstration of brain region-specific neuronal vulnerability in human iPSC-based model of familial Parkinson's disease.
    Brazdis RM; Alecu JE; Marsch D; Dahms A; Simmnacher K; Lörentz S; Brendler A; Schneider Y; Marxreiter F; Roybon L; Winner B; Xiang W; Prots I
    Hum Mol Genet; 2020 May; 29(7):1180-1191. PubMed ID: 32160287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease.
    Hallett PJ; Deleidi M; Astradsson A; Smith GA; Cooper O; Osborn TM; Sundberg M; Moore MA; Perez-Torres E; Brownell AL; Schumacher JM; Spealman RD; Isacson O
    Cell Stem Cell; 2015 Mar; 16(3):269-74. PubMed ID: 25732245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease.
    Burbulla LF; Jeon S; Zheng J; Song P; Silverman RB; Krainc D
    Sci Transl Med; 2019 Oct; 11(514):. PubMed ID: 31619543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.